Adjunctive Vagus Nerve Stimulation for Treatment-Resistant Depression: a Quantitative Analysis

被引：0
作者：
Xun Zhang
Ming-Jun Qing
Ying-Hua Rao
Yan-Mei Guo
机构：
[1] The Affiliated Brain Hospital of Guangzhou Medical University (Guangzhou Huiai Hospital),Department of Neurosurgery
[2] The Third Affiliated of Guangzhou Medical University,Department of Intensive Care Unit
来源：
Psychiatric Quarterly | 2020年 / 91卷
关键词：
Vagus nerve stimulation; Treatment-resistant depression; Depressive symptoms; Safety; Meta-analysis;
D O I：
暂无
中图分类号：
学科分类号：
摘要：
Vagus nerve stimulation (VNS) has been increasingly studied in treating treatment-resistant depression (TRD), but the findings have been mixed. This updated meta-analysis was conducted to examine the efficacy and safety of adjunctive VNS for TRD. Controlled studies reporting on the efficacy and safety of adjunctive VNS for TRD were screened, identified and analyzed. Standardized mean difference (SMD), risk ratio (RR) and their 95% confidence intervals (CIs) were analyzed using RevMan version 5.3. Three controlled studies with a total of 1048 patients with TRD compared VNS (n = 622) with control (n = 426) groups. Only one study was rated as ‘high quality’ using the Jadad scale. Adjunctive VNS was significantly superior to the control group regarding study-defined response [SMD:1.96 (95%CI:1.60, 2.40), P < 0.00001, I2 = 0%]. Patient-reported voice alteration occurred more frequently with adjunctive VNS for patients with TRD. No significant group differences were found regarding discontinuation due to any reason [RR:0.50 (95%CI:0.12, 2.09), P = 0.34, I2 = 85%]. Adjunctive VNS appeared to be effective and relatively safe treatment for TRD. Further randomized controlled trials are needed to confirm the efficacy and safety of VNS for TRD.
引用
收藏
页码：669 / 679
页数：10
相关论文
共 301 条
  • [1] Vigo D(2016)Estimating the true global burden of mental illness Lancet Psychiatry 3 171-178
  • [2] Thornicroft G(2003)Diagnosis and definition of treatment-resistant depression Biol Psychiatry 53 649-659
  • [3] Atun R(2015)Safety and tolerability of antidepressant co-treatment in acute major depressive disorder: results from a systematic review and exploratory meta-analysis Expert Opin Drug Saf 14 1587-1608
  • [4] Fava M(2015)Atypical antipsychotic augmentation for treatment-resistant depression: a systematic review and network meta-analysis Int J Neuropsychopharmacol 18 pyv060-190
  • [5] Galling B(2013)Lithium or an atypical antipsychotic drug in the management of treatment-resistant depression: a systematic review and economic evaluation Health Technol Assess (Winch. Engl.) 17 1-501
  • [6] Calsina Ferrer A(2019)Investigation of medical effect of multiple ketamine infusions on patients with major depressive disorder J Affect Disord 33 494-68
  • [7] Abi Zeid Daou M(2018)Rapid and longer-term antidepressant effects of repeated-dose intravenous ketamine for patients with unipolar and bipolar depression J Psychopharmacol (Oxford, England) 106 61-158
  • [8] Sangroula D(2018)The effect of a single dose of intravenous ketamine on suicidal ideation: a systematic review and individual participant data meta-analysis Am J Psychiatry 175 150-1472
  • [9] Hagi K(2016)Single-dose infusion ketamine and non-ketamine N-methyl-d-aspartate receptor antagonists for unipolar and bipolar depression: a meta-analysis of efficacy, safety and time trajectories Psychol Med 46 1459-630
  • [10] Correll CU(2018)Efficacy and safety of intranasal Esketamine for the rapid reduction of symptoms of depression and Suicidality in patients at imminent risk for suicide: results of a double-blind, randomized, placebo-controlled study Am J Psychiatr 175 620-148
12345678910